Prognostic Factors and Nomogram Predicting Survival in Diffuse Astrocytoma

Abstract

Background Prognosis of low-grade glioma are currently determined by genetic markers that are limited in some countries. This study aimed to use clinical parameters to develop a nomogram to predict survival of patients with diffuse astrocytoma (DA) which is the most common type of low-grade glioma. Materials and Methods Retrospective data of adult patients with DA from three university hospitals in Thailand were analyzed. Collected data included clinical characteristics, neuroimaging findings, treatment, and outcomes. Cox's regression analyses were performed to determine associated factors. Significant associated factors from the Cox regression model were subsequently used to develop a nomogram for survival prediction. Performance of the nomogram was then tested for its accuracy. Results There were 64 patients with DA with a median age of 39.5 (interquartile range [IQR] = 20.2) years. Mean follow-up time of patients was 42 months (standard deviation [SD] = 34.3). After adjusted for three significant factors associated with survival were age ≥60 years (hazard ratio [HR] = 5.8; 95% confidence interval [CI]: 2.09-15.91), motor response score of Glasgow coma scale < 6 (HR = 75.5; 95% CI: 4.15-1,369.4), and biopsy (HR = 0.45; 95% CI: 0.21-0.92). To predict 1-year mortality, sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and area under the curve our nomogram was 1.0, 0.50, 0.45, 1.0, 0.64, and 0.75, respectively. Conclusions This study provided a nomogram predicting prognosis of DA. The nomogram showed an acceptable performance for predicting 1-year mortality. AbstractKeywords ► diffuse astrocytoma ► nomogram ► survival analysis

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma

“…Therefore, selecting GBM patients by predicted favorable prognosis has been proposed for the likelihood of TMZ cost-effectiveness in real-world situations. 24 Nomogram is one of the clinical prediction tools (CPT) that have been used for various diseases such as cancer, 25 trauma, 26,27 or degenerative disease. 28 Therefore, we proposed a web-based nomogram for prognostication that will be applied for selecting patients with a favorable prognosis when low-or middle-income settings need to allocate resources.…”

Low Fraction Size Re-irradiation for Large Volume Recurrence of Glial Tumours

“…In our patient group, the median survival according to the histopathological grade was higher than in other reported studies (the median survival is around 55-60 months for grade 2 and 18-26 months for grade 3 tumours). [41]. It could be explained with the natural patient selection and the younger age (inclusion of paediatric patients).…”

Evaluation of novel radiotherapy approaches in brain tumour management

“…In our patient group, the median survival according to the histopathological grade was higher than in other reported studies (the median survival is around 55-60 months for grade 2 and 18-26 months for grade 3 tumours). [82]. It could be explained with the natural patient selection and the younger age (inclusion of paediatric patients).…”

“…This technique allowed encompassing even 10-12 metastases into the boost volume, and lasted only 3 weeks, considered reasonable for patients with poorer condition. Tiwari and co-workers reported the results of SIB of 19 patients versus WBRT alone (13 patients), demonstrating better local control and improved survival in the SIB group [41]. Another publication from Italian groups emphasises the higher efficacy of the intensified treatment (WBRT and SRS boost), as well, enrolling 134 patients, of whom 21 were treated with SIB [28].…”

“…Targeted agents have been applied primarily in HER2-positive breast cancer patients with brain metastases [40]. The lapatinib-capecitabine combination therapy resulted in response rates of 66% (patients with no prior radiotherapy) 20% (radiation refractory patients); according to recent phase II studies [41,42,43] The optimal selection of SRS versus WBRT in the management of brain metastasis remains to be answered [34].…”